Partnering Today for a Stronger Tomorrow: Beckman Coulter Showcases Solutions for Navigating the Changing Healthcare Landscape

Beckman Coulter Diagnostics goes beyond technology solutions to help customers improve patient care, increase quality and lower costs.

BREA, Calif. — (July 20, 2017) — Beckman Coulter Diagnostics, a global leader in the clinical diagnostics industry will present its global initiative, “Partnering Today for a Stronger Tomorrow,” at the 69th American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Laboratory Expo (CLE) in San Diego, Calif. From July 31–Aug 4, attendees can visit booth #3117 to discover the Beckman Coulter Diagnostics Difference?a unique integrated partnership solution comprised of tools, insights, management systems and process improvements, created to help laboratories achieve operational and clinical excellence.

“We look forward to collaborating with our colleagues and partners at AACC this year to further relationships and deepen understanding. We know that, as significant changes occur in the healthcare landscape, our clinical partners face a host of challenges that require new ways of thinking,” said Arnd Kaldowski, president, Beckman Coulter Diagnostics and Group Executive Diagnostics for Danaher. “We believe that patient care begins with the clinical laboratory. Helping serve patients in the safest and most efficient manner is our job, and, in fact, it is our vision to advance healthcare for every person.”

At the heart of the Beckman Coulter Diagnostics Difference, are the company’s comprehensive high-quality clinical diagnostics solutions—exemplified by several new products featured in the booth this year, including the:


  • DxC 700 AU chemistry analyzer, ideal for mid- to high-volume clinical laboratories
  • Procalcitonin chemistry assay for early detection and management of bacterial infections
  • Access AMH assay* for women’s health and fertility assessments
  • Access 2 immunoassay analyzer, featuring new enhancements for ease-of-use and productivity
  • DxH 500 hematology analyzer,** designed for physician offices and other laboratories with low-volume workloads
  • DxM 1096 MicroScan WalkAway System,*** featuring a design update for ease-of-use
  • DxONE portfolio of information management tools, created to ease data access and usability, and empower more confident decision making
  • REMISOL Advance middleware solutions, bridging laboratory information systems (LIS) and instrumentation to provide real-time operational insights to improve laboratory efficiencies


The launch of these new products further expands portfolio of clinical diagnostic solutions offered by the diagnostic companies of Danaher Corporation, which include Beckman Coulter, Cepheid, Leica Biosystems, Radiometer, and SCIEX Diagnostics. The breadth of this portfolio extends from the established to novel diagnostic technologies for clinical and anatomic pathology laboratories and point-of-care testing. With a rich history and a tradition of innovation, the diagnostic companies of Danaher remain committed to developing of new and unique diagnostic approaches for better, integrated patient care, and to helping the healthcare systems build comprehensive and efficient diagnostic services with high degree of automation, standardization and connectivity.

Laboratorians and healthcare professionals can learn more about Beckman Coulter Diagnostics solutions by participating in the company-hosted educational programs and in-booth presentations listed below. Detailed information is available here.

Tuesday, August 1, 1:00 to 2:00 pm

Sepsis and the Hematology Laboratory 
In this session, the clinical and laboratory-related characteristics of sepsis are described, with special emphasis on hematologic manifestations of sepsis.
Speaker: Mike Samoszuk, M.D., Beckman Coulter


Wednesday, August 2, 10:30 am to 12:00 pm

The ASSESS Trial: A Multi-instrument Evaluation of 13 Commercial Troponin Assays, Sample Analysis in a Common Cohort of Samples
Moderator: Robert Christenson, Ph.D., University of Maryland School of Medicine
Speakers: Allison Chambliss, Ph.D., Keck School of Medicine of University of Southern California; Paramjit Sandhu, M.D., MPH, Centers for Disease Control and Prevention; Alan Wu, Ph.D., University of California San Francisco General Hospital

Beckman Coulter In-booth Education Sessions

Procalcitonin and its Role as a Biomarker for the Management of Sepsis
Sherry Faye, Ph.D.
Tuesday, August 1, 12:00 pm 

New Challenges for Microbiology Laboratories in Antibiotic Susceptibility Testing
Barbara Zimmer, Ph.D.
Tuesday, August 1, 1:00 pm 

H&H Testing: The Rule of Three Is Still Relevant
Ahmed Bentahar M.D., Ph.D.
Tuesday, August 1, 2:00 pm 

High-sensitivity Cardiac Troponin: What Does It Mean for Your Laboratory, Your Clinicians and Your Patients?
Peter Kavsak Ph.D., FCACB, FACB, FCCS
Tuesday, August 1, 3:00 pm 

DxONE Innovative Informatics
Santosh Kookal
Wednesday, August 2, 11:00 am 

Prostate Health Index (phi): A Simple Blood Test to Reduce Unnecessary Biopsies
Jay White, Ph.D., MPH
Wednesday, August 2, 12:00 pm 

Three Clinical Rules for Laboratory Survival
Diane Janowlak
Wednesday, August 2, 1:00 pm 

Automated Platelet Counting: Technical and Clinical Considerations
Mike Samoszuk M.D.
Wednesday, August 2, 2:00 pm 

Introducing DxONE Inventory Manager
Sunil Daryanani
Wednesday, August 2, 3:00 pm 

Introducing the Topaz System: A Simplified LCMS Experience
Crystal Holt, M.S.
Wednesday, August 2, 4:00 pm 

Leveraging Service and Care Through Real-time Analysis of Provider Relationships and Behavior
Connor Billing
Thursday, August 3, 10:00 am 

9:30 am to 5:00 pm ¦ Tuesday, August 1 or Wednesday, August 2 
Authors will be available at posters from 12:30 to 1:30 pm for discussion with attendees. 

A Prospective Observational Study of the Clinical Decision Impact on the Prostate Health Index (phi) Test in a Urology Practice Setting (A-141) 

A Comparison of the New Beckman Coulter DxC 700 AU Clinical Chemistry System to the UniCel DxC 800 Synchron Clinical Systems (B-440) 

Characteristics of the New Beckman Coulter Access hsTnI Assay (TBD) 

Biomarker Changes in Adult Men with Low Testosterone (low-T) (A-172) 

Improvement to Workflow in Reagent Dispense System Design in the New Beckman Coulter DxM MicroScan WalkAway System (B-075) 

Multicenter Evaluation of Imipenem MIC Results for Gram Negative Bacilli Using MicroScan Dried Gram Negative MIC Panels (A-123) 

Easy as 1, 2, 3? Trimester-specific TSH Reference Intervals in a Well-Characterized Population Using the Beckman Coulter (3rd IS) Immunoassay (TBD) 

Early Development of DxONE Insights, a Tool to Enhance Data-Driven Decision Making to Improve Laboratory Efficiency (B-028) 

Analyzer Maintenance Affects the Observable Sigma Metrics of Clinical Chemistry Analytes (A-234) 

About Beckman Coulter

Beckman Coulter Diagnostics helps healthcare and laboratory professionals provide better patient care by delivering the accurate diagnostic information they need, when they need it. For more than 80 years, Beckman Coulter has been the partner of choice for healthcare organizations. Our scalable instruments, comprehensive diagnostic tests and business management services are trusted by hospitals, laboratories and other critical care settings around the world. We share in our customers' mission toward continuous improvement and quality patient care, because we believe when efficiency and clinical outcomes are improved, patients benefit, and we can move healthcare forward for every person.

Beckman Coulter, the stylized logo and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.


Beckman Coulter, the stylized logo and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.


*Pending 510(k) clearance by the United States Food and Drug Administration; not yet available for in vitro diagnostic use in the United States.

**Under development. The performance characteristics of this product have not been established.

***Not yet available for in vitro diagnostic use. Pending achievement of CE compliance, Canadian Licensure and other regulatory registrations. REMISOL Advance is a trademark or registered trademark of Normand-Info SAS in the United States and other countries. Used under license.

Cepheid and GeneXpert are trademarks of Cepheid in the United States and other countries.